Rheumatic And Dermatologic Diseases
ZBIOZenas BioPharmaCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ZB021 (IL-17AA/AF Inhibitor) in Rheumatic And Dermatologic Diseases. The expected timing is based on the latest available company guidance and may change.
03/16/26:- ZB021 oral IL-17AA/AF inhibitor Phase 1 trial expected to initiate in Q2 2026; initial data by YE 2026. 05/13/26:- First subject dosed in ZB021 Ph1 SAD/MAD trial; initial safety data expected Q4 2026; psoriasis POC results 2027. North America plaque psoriasis POC planned. 08/13/26:- ZB021 Ph1 SAD and MAD dosing is ongoing. Initial data are expected by year-end 2026; psoriasis POC results are expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.